Saturnus Bio

Saturnus Bio is a private, research-stage precision cardiology biotechnology company focused on developing first-in-class therapies for rare genetic cardiomyopathies. The company was founded by Versant Ventures and launched through a strategic build-to-buy collaboration with Merck KGaA, Darmstadt, Germany, with EMD Serono representing the partnership in the U.S. and Canada. Saturnus is using targeted gene modulation to build a foundational portfolio of medicines for monogenic cardiomyopathies with high unmet need. Merck provided an upfront $50 million research commitment and secured a minority equity stake plus exclusive acquisition rights tied to option payments and milestones. The company appears to be at the preclinical stage, and specific gene targets and individual development candidates have not yet been publicly disclosed.